“Myositis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myositis Market.
The Myositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Myositis Pipeline Report:
Companies across the globe are diligently working toward developing novel Myositis treatment therapies with a considerable amount of success over the years.
Myositis companies working in the treatment market are JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others, are developing therapies for the Myositis treatment
Emerging Myositis therapies in the different phases of clinical trials are- HuABC2, PF1801, PN-101, M5049, and others are expected to have a significant impact on the Myositis market in the coming years.
In March 2025, Abcuro, Inc., a clinical-stage biotech firm focused on treating autoimmune diseases and cancer by precisely targeting cytotoxic T cells, announced it will present safety, pharmacokinetic, and pharmacodynamic findings from its Phase 1 clinical trial of ulviprubart (ABC008) for inclusion body myositis (IBM) at the upcoming American Academy of Neurology (AAN) Annual Meeting.
In February 2025, Abcuro secured $200 million in Series C funding to advance the development of its first-in-class therapy for inclusion body myositis. The funding will support the completion of the registrational Phase 2/3 MUSCLE trial evaluating ulviprubart, as well as the preparation for its Biologics License Application (BLA) submission and eventual commercial launch.
In November 2024, argenx has chosen to advance the development of efgartigimod SC (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA trial for adults with idiopathic inflammatory myopathies. This decision follows positive topline results from the Phase 2 segment, where the study met its primary endpoint by showing a statistically significant improvement in the mean total improvement score (TIS) at Week 24. Moreover, efgartigimod SC demonstrated favorable outcomes across all six core TIS measures compared to placebo.
Myositis Overview
Myositis is a rare autoimmune disease characterized by inflammation and weakness of the skeletal muscles, particularly those closest to the trunk of the body. It is classified as an idiopathic inflammatory myopathy, meaning that its exact cause is unknown. However, it is believed to involve an abnormal immune response in which the body’s immune system mistakenly attacks its own muscles.
Get a Free Sample PDF Report to know more about Myositis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myositis-pipeline-insight
Emerging Myositis Drugs Under Different Phases of Clinical Development Include:
HuABC2: JN Biosciences
PF1801: ImmunoForge
PN-101: Paean Biotechnology Inc.
M5049: Merck KGaA
Myositis Route of Administration
Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Myositis Molecule Type
Myositis Products have been categorized under various Molecule types, such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Myositis Pipeline Therapeutics Assessment
Myositis Assessment by Product Type
Myositis By Stage and Product Type
Myositis Assessment by Route of Administration
Myositis By Stage and Route of Administration
Myositis Assessment by Molecule Type
Myositis by Stage and Molecule Type
DelveInsight’s Myositis Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Myositis product details are provided in the report. Download the Myositis pipeline report to learn more about the emerging Myositis therapies
Some of the key companies in the Myositis Therapeutics Market include:
Key companies developing therapies for Myositis are – F. Hoffmann-La Roche Ltd, Pfizer Inc, Zydus Group, Lupin, Bausch Health Companies Inc., Accord Healthcare, Genentech, Inc, Johnson & Johnson Services, Inc., Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy’s Laboratories Ltd, Abbott, Bristol-Myers Squibb Company, GSK plc, Merz Pharma, Akorn, Incorporated, and others.
Myositis Pipeline Analysis:
The Myositis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Myositis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myositis Treatment.
Myositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myositis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Myositis drugs and therapies
Myositis Pipeline Market Drivers
Growing cases of chronic muscle inflammation, continuous advancement in technology, increased injuries of muscle are some of the important factors that are fueling the Myositis Market.
Myositis Pipeline Market Barriers
However, high cost of drugs, lack of approved therapies and other factors are creating obstacles in the Myositis Market growth.
Scope of Myositis Pipeline Drug Insight
Coverage: Global
Key Myositis Companies: JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others
Key Myositis Therapies: HuABC2, PF1801, PN-101, M5049, and others
Myositis Therapeutic Assessment: Myositis current marketed and Myositis emerging therapies
Myositis Market Dynamics: Myositis market drivers and Myositis market barriers
Request for Sample PDF Report for Myositis Pipeline Assessment and clinical trials
Table of Contents
1. Myositis Report Introduction
2. Myositis Executive Summary
3. Myositis Overview
4. Myositis- Analytical Perspective In-depth Commercial Assessment
5. Myositis Pipeline Therapeutics
6. Myositis Late Stage Products (Phase II/III)
7. Myositis Mid Stage Products (Phase II)
8. Myositis Early Stage Products (Phase I)
9. Myositis Preclinical Stage Products
10. Myositis Therapeutics Assessment
11. Myositis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Myositis Key Companies
14. Myositis Key Products
15. Myositis Unmet Needs
16 . Myositis Market Drivers and Barriers
17. Myositis Future Perspectives and Conclusion
18. Myositis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
